ArticleJournal of the American College of Cardiology2022
Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults.
Open access · greenAbstract read
In one paragraph
Article in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
9.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.Journal of clinical immunology · 2026Pooled it
- Characteristics and Outcomes of Multisystemic Inflammation in Patients Clinically Diagnosed With Non-COVID-19-Related Fulminant Myocarditis.Circulation reports · 2026Article
- Shared TCR Vβ21.3+ T cell immunological signature between MIS-A and MIS-C.Journal of human immunity · 2026Article
- Effects of Cardiac Remodeling and Altered Mechanics on Cardiac Outcomes in Fulminant Myocarditis in Children: Insight from a Longitudinal Pilot Study.Pediatric cardiology · 2026Article
- Long-term left ventricular ejection function in fulminant and non-fulminant myocarditis: A multicenter study in China.International journal of cardiology. Heart & vasculature · 2025Article
- Prognostic Factors Associated With Early Recovery From Veno-Arterial Extracorporeal Membrane Oxygenation Support in Patients With Fulminant Myocarditis.Journal of the American Heart Association · 2025Article
- Cardiogenic shock in systemic sclerosis: a retrospective study of acute ventricular dysfunction.Rheumatology international · 2025Observational
- Deep insight into cytokine storm: from pathogenesis to treatment.Signal transduction and targeted therapy · 2025Review
- Anti-RNApol3-Associated myocarditis: an emerging disease linking autoimmunity and infection.Annals of intensive care · 2025Article
- Article
- A Multicenter Retrospective Cohort Study to Characterize Patients Hospitalized With Multisystem Inflammatory Syndrome in Adults and Coronavirus Disease 2019 in the United States, 2020-2021.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Myocarditis and COVID-19 related issues.Global cardiology science & practice · 2023Review
- Immunopathogenesis and immunomodulatory therapy for myocarditis.Science China. Life sciences · 2023Review
- Diagnostic yield, safety and therapeutic consequences of myocardial biopsy in clinically suspected fulminant myocarditis unweanable from mechanical circulatory support.Annals of intensive care · 2023Article
- Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management.Revista espanola de cardiologia (English ed.) · 2023Article
- [Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].Revista espanola de cardiologia · 2023Article
- COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors.International journal of molecular sciences · 2023Review
- How Does COVID-19 Affect the Heart?Current cardiology reports · 2023Review
- Current Knowledge of Th22 Cell and IL-22 Functions in Infectious Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Clinical and biological heterogeneity of multisystem inflammatory syndrome in adults following SARS-CoV-2 infection: a case series.Frontiers in medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 2 institutions in 2 countries.
Petra BarhoumSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France.
Marc Pineton de ChambrunSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France; Sorbonne Université, Inserm, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
Karim DorghamSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
Mathieu KerneisSorbonne Université, Inserm, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, ACTION Study Group, Département de Cardiologie, Paris, France.
Sonia BurrelSorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), INSERM U1136, Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Virologie, Paris, France.
Paul QuentricSorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
Christophe ParizotSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
Juliette ChommelouxSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France.
Nicolas BréchotSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France.
Quentin MoyonSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France.
Guillaume LebretonSorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Chirurgie Cardio-Thoracique, Paris, France.
Samia BoussouarSorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Unité d'Imagerie Cardiovasculaire et Thoracique (ICT), Paris, France.
Matthieu SchmidtSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France; Sorbonne Université, Inserm, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France.
Hans YsselSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
Lucie LefevreSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France.
Makoto MiyaraSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
Jean-Luc CharuelSorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
Stéphane MarotSorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), INSERM U1136, Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Virologie, Paris, France.
Anne-Geneviève MarcelinSorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), INSERM U1136, Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Virologie, Paris, France.
Charles-Edouard LuytSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France; Sorbonne Université, Inserm, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France.
Pascal LeprinceSorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Chirurgie Cardio-Thoracique, Paris, France.
Zahir AmouraSorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France.
Gilles MontalescotSorbonne Université, Inserm, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, ACTION Study Group, Département de Cardiologie, Paris, France.
Alban RedheuilSorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Unité d'Imagerie Cardiovasculaire et Thoracique (ICT), Paris, France.
Alain CombesSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France; Sorbonne Université, Inserm, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France.
Guy GorochovSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France; Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France. Electronic address: guy.gorochov@sorbonne-universite.fr.
Guillaume HékimianSorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Paris, France. Electronic address: guillaume.hekimian@aphp.fr.
Inserm · FRSorbonne Université · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdults who have been infected with SARS-CoV-2 can develop a multisystem inflammatory syndrome (MIS-A), including fulminant myocarditis. Yet, several patients fail to meet MIS-A criteria, suggesting the existence of distinct phenotypes in fulminant COVID-19-related myocarditis.
objectivesThis study sought to compare the characteristics and clinical outcome between patients with fulminant COVID-19-related myocarditis fulfilling MIS-A criteria (MIS-A
methodsA monocentric retrospective analysis of consecutive fulminant COVID-19-related myocarditis in a 26-bed intensive care unit (ICU).
resultsBetween March 2020 and June 2021, 38 patients required ICU admission (male 66%; mean age 32 ± 15 years) for suspected fulminant COVID-19-related myocarditis. In-ICU treatment for organ failure included dobutamine 79%, norepinephrine 60%, mechanical ventilation 50%, venoarterial extracorporeal membrane oxygenation 42%, and renal replacement therapy 29%. In-hospital mortality was 13%. Twenty-five patients (66%) met the MIS-A criteria. MIS-A
conclusionMIS-A
Indexed as
COVID-19MyocarditisAdolescentAdultAntibodies, AntinuclearAutoantibodiesFemaleHumansMaleMiddle AgedPhenotypeRetrospective StudiesSARS-CoV-2Stroke VolumeSystemic Inflammatory Response SyndromeVentricular Function, LeftAntibodies, Antinuclearanti-RNA-polymerase III autoantibodyAutoantibodiesCOVID-19cytokinesfulminant myocarditismultisystem inflammatory syndromeRNA polymerase III autoantibodiesSARS-CoV-2VA-ECMO
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.